If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

PFIZi030-A

B216c13

iPSC line

Not-for-profit fee: £1400 per vial
Immediately available for distribution*
*Once all legal and processing details completed
Timepoint: Confluency
Magnification: x4
Timepoint: Confluency
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name PFIZi030-A
Alternative name(s)
B216c13
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.

Provider

Depositor Pfizer Limited - Pfizer (PFIZ)
Distributors
EBiSC

External Databases

hPSCreg PFIZi030-A
BioSamples SAMEA104492931
Cellosaurus CVCL_VE78
Wikidata Q54947284

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no

Donor Information#

General Donor Information

Sex female
Age of donor (at collection) 15-19

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Genetic variants
NPR2 (target)
9p13.3
NM_003995.4:c.890C>T
NP_003986.2:p.Thr297Met
P.Thr297Met (ACG>ATG) c.890 C>T in exon 3 in the NPR2 gene

External Databases (Donor)

BioSamples SAMEA104492930

hIPSC Derivation#

General

Source cell type
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
Age of donor (at collection) 15-19

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
Unknown

Culture Conditions#

Latest released batch

Culture medium mTeSR™1
Passage method EDTA
Surface coating Matrigel / Geltrex
O2 concentration 21
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
GATA6
Yes
CXCR4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
Vimentin
Yes
NCAM
Yes
MIXL1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
NeuroD1
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX modal karyotype in 20 cells showed a normal female chromosome and complement banding pattern
Passage number: 14

Other Genotyping (Cell Line)